Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Inventory (2021 - 2025)

Historic Change in Inventory for Apellis Pharmaceuticals (APLS) over the last 5 years, with Q3 2025 value amounting to -$5.4 million.

  • Apellis Pharmaceuticals' Change in Inventory rose 3758.52% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.4 million, marking a year-over-year decrease of 10497.43%. This contributed to the annual value of $10.8 million for FY2024, which is 8226.62% down from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Change in Inventory of -$5.4 million as of Q3 2025, which was up 3758.52% from $26.0 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Change in Inventory ranged from a high of $47.8 million in Q4 2023 and a low of -$14.0 million during Q1 2025
  • Over the past 5 years, Apellis Pharmaceuticals' median Change in Inventory value was $14.5 million (recorded in 2024), while the average stood at $9.4 million.
  • In the last 5 years, Apellis Pharmaceuticals' Change in Inventory surged by 1046180.56% in 2024 and then crashed by 19380.74% in 2025.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Change in Inventory stood at $14.6 million in 2021, then soared by 77.33% to $26.0 million in 2022, then surged by 84.18% to $47.8 million in 2023, then crashed by 120.96% to -$10.0 million in 2024, then soared by 46.09% to -$5.4 million in 2025.
  • Its last three reported values are -$5.4 million in Q3 2025, $26.0 million for Q2 2025, and -$14.0 million during Q1 2025.